"An analysis of 927 confirmed symptomatic COVID-19 cases demonstrates the high efficacy of BNT162b2 ... at 91.3% measured from seven days to six months after the second dose," the press release said.
In addition, the vaccine has shown 100% (according to the US Centers for Disease Control and Prevention) and 95.3% (according to the US Food and Drug Administration) effectiveness in preventing severe cases of coronavirus.
At the same time, Pfizer / BioNTech also proved to be 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 mutation is predominantly common.
The safety of the drug this time was assessed on more than 44 thousand volunteers over 16 years old, 12 thousand of whom received the second component of the vaccine no later than six months ago.
In November, Pfizer and BioNTech announced that their coronavirus vaccine was 95% effective.